NASDAQ:TTPH Tetraphase Pharmaceuticals (TTPH) Stock Price, News & Analysis → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free TTPH Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.18▼$2.2750-Day Range$2.20▼$2.2052-Week Range$0.56▼$8.60Volume282,689 shsAverage Volume932,542 shsMarket Capitalization$15.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Tetraphase Pharmaceuticals alerts: Email Address Ad The Oxford ClubAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time to watch it.Watch Alex's "Next Magnificent Seven" presentation now. About Tetraphase Pharmaceuticals Stock (NASDAQ:TTPH)Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.Read More Ad The Oxford ClubAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time to watch it.Watch Alex's "Next Magnificent Seven" presentation now. TTPH Stock News HeadlinesFebruary 26, 2023 | benzinga.comInfinity Pharmaceuticals Stock (NASDAQ:INFI), Quotes and News SummaryAugust 30, 2022 | thestreet.comTetraphase Pharmaceuticals (TTPH) Stock Tanks on Weak Phase 3 Test ResultsAugust 20, 2022 | thestreet.comTetraphase Executive Profits Hours Before Stock PlummetsApril 4, 2022 | investing.comTTPH_old Historical DataJanuary 16, 2022 | thestreet.com10 Worst NASDAQ Biotech Stocks in the Third QuarterSee More Headlines Receive TTPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tetraphase Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2020Today6/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:TTPH CUSIPN/A CIK1373707 Webwww.tphase.com Phone617-715-3600FaxN/AEmployees119Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($22.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,080,000.00 Net Margins-798.18% Pretax MarginN/A Return on Equity-210.86% Return on Assets-121.73% Debt Debt-to-Equity Ratio0.06 Current Ratio3.66 Quick Ratio3.56 Sales & Book Value Annual Sales$7.38 million Price / Sales2.17 Cash FlowN/A Price / Cash FlowN/A Book Value$6.68 per share Price / Book0.33Miscellaneous Outstanding Shares7,263,000Free FloatN/AMarket Cap$15.98 million OptionableOptionable Beta2.33 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Guy MacDonald B.Sc. (Age 60)B.Sc, CEO, Pres & Director Mr. Christopher Watt (Age 54)Principal Financial & Accounting Officer Dr. Jacques Dumas (Age 53)Chief Scientific Officer Ms. Maria D. Stahl (Age 48)Sr. VP & Gen. Counsel Mr. Larry G. Edwards (Age 47)Chief Operating Officer Key CompetitorsCheckpoint TherapeuticsNASDAQ:CKPTImmix BiopharmaNASDAQ:IMMXTheratechnologiesNASDAQ:THTXCalciMedicaNASDAQ:CALCLeap TherapeuticsNASDAQ:LPTXView All Competitors TTPH Stock Analysis - Frequently Asked Questions How were Tetraphase Pharmaceuticals' earnings last quarter? Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) released its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($1.31) EPS for the quarter, beating the consensus estimate of ($1.63) by $0.32. The biopharmaceutical company had revenue of $1.76 million for the quarter, compared to analysts' expectations of $2.45 million. Tetraphase Pharmaceuticals had a negative trailing twelve-month return on equity of 210.86% and a negative net margin of 798.18%. When did Tetraphase Pharmaceuticals' stock split? Tetraphase Pharmaceuticals shares reverse split on Friday, September 27th 2019. The 1-20 reverse split was announced on Thursday, September 26th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 26th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Tetraphase Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tetraphase Pharmaceuticals investors own include Aurinia Pharmaceuticals (AUPH), Alcoa (AA), General Electric (GE), OPKO Health (OPK), Novavax (NVAX), Bank of America (BAC), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO) and Synergy Pharmaceuticals (SGYP). This page (NASDAQ:TTPH) was last updated on 6/4/2024 by MarketBeat.com Staff From Our PartnersWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises| SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club| Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC| SponsoredWhat’s Pelosi Buying Now?They Make the Top Investors Look Like Amateurs They beat the market for three years straight… avoided some ...Altimetry| Sponsored[Urgent!] Generational Wealth GameplanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan ...Crypto 101 Media| SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings| SponsoredAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro| SponsoredClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an eff...Crypto Swap Profits| Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tetraphase Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Tetraphase Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.